Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant vs Amiodarone for Post-operative Atrial Fibrillation
NCT04748991Phase 3Not yet recruiting
- Sponsor
- University of Calgary
- Start
- Sep 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of vernakalant in Atrial fibrillation (AFib), sponsored by University of Calgary. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT04748991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748991.